Medtronic Inc. said Wednesday that Canadian regulators approved its Arctic Front cardiac cryoablation catheter system, which treats abnormal heart rhythms using extreme cold.
The world's largest medical device maker said the Arctic Front system treats a type of irregular heartbeat called atrial fibrillation. It uses cold to destroy some tissue, creating lesions around the pulmonary vein, the source of the signals that cause the irregular heartbeat.
Atrial fibrillation is a condition in which the upper chambers of the heart do not beat in sync with the lower chambers.
Medtronic acquired the Arctic Front system in November 2008, when it bought Canadian heart device maker CryoCath in a deal valued at about $380 million.